Literature DB >> 6466871

Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases.

C Rozman, E Montserrat, J M Rodríguez-Fernández, R Ayats, T Vallespí, R Parody, A Ríos, D Prados, M Morey, F Gomis.   

Abstract

In previous studies, the prognostic value of bone marrow (BM) histologic patterns in chronic lymphocytic leukemia (CLL) has been demonstrated. In order to investigate whether such a value is independent of other prognostic parameters, a multivariate survival analysis (Cox's regression model) was undertaken in a series of 329 CLL patients in whom a BM had been performed. The following binary variables were included in the analysis: age (more than 60 years), lymphadenopathy (more than two areas involved), splenomegaly, hepatomegaly, absolute lymphocyte count (more than 30,000 microL), anemia (hemoglobin less than 10 g/dL), thrombocytopenia (less than 100,000 microL), and BM pattern (diffuse v nondiffuse). Three variables entered the regression at significant level: BM pattern (P less than .001), anemia (P less than .001), and hepatomegaly (P = .03). The model was also tested by expressing the variables in a continuous way when possible. Again, BM pattern entered first in the regression (P less than .001), followed by the hepatomegaly (P = .002), hemoglobin level (P = .02), and lymphadenopathy (P = .04). When both the binary and the continuous models were tested separately in 227 patients with BM as initial staging procedure and in 102 patients in whom this was performed later during the course of the disease, in all instances, BM pattern entered first in the regression at a highly significant level. BM histologic pattern appears to be a better single prognostic parameter than any one of the variables employed in current clinical staging systems. A combined clinicopathologic system incorporating the BM pattern, together with the usual clinical variables, is presented.

Entities:  

Mesh:

Year:  1984        PMID: 6466871

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  Reticulin fibre content of bone marrow infiltrates of malignant non-Hodgkin's lymphomas (B-cell type, low malignancy)--a morphometric evaluation before and after therapy.

Authors:  J Thiele; J Langohr; M Skorupka; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia.

Authors:  Roberto Marasca; Rossana Maffei; Monica Morselli; Patrizia Zucchini; Ilaria Castelli; Silvia Martinelli; Marcella Fontana; Sara Ravanetti; Monica Curotti; Giovanna Leonardi; Katia Cagossi; Giovanni Partesotti; Giuseppe Torelli
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

3.  A population-based assessment of the prognostic value of the CD19 positive lymphocyte count in B-cell chronic lymphocytic leukemia using Cox and Markov models.

Authors:  R Cailliod; C Quantin; P M Carli; V Jooste; G Le Teuff; C Binquet; M Maynadie
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

4.  Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease.

Authors:  Aaron Burberry; Naoki Suzuki; Jin-Yuan Wang; Rob Moccia; Daniel A Mordes; Morag H Stewart; Satomi Suzuki-Uematsu; Sulagna Ghosh; Ajay Singh; Florian T Merkle; Kathryn Koszka; Quan-Zhen Li; Leonard Zon; Derrick J Rossi; Jennifer J Trowbridge; Luigi D Notarangelo; Kevin Eggan
Journal:  Sci Transl Med       Date:  2016-07-13       Impact factor: 17.956

5.  Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  J Clin Pathol       Date:  1989-06       Impact factor: 3.411

Review 6.  Management of chronic lymphocytic leukaemia.

Authors:  N Kalil; B D Cheson
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

7.  Intravenous immune globulin in chronic lymphocytic leukaemia.

Authors:  H Gamm; C Huber; H Chapel; M Lee; F Ries; M A Dicato
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia.

Authors:  Stefano Molica; Gaetano Vitelli; Giovanna Cutrona; Katia Todoerti; Rosanna Mirabelli; Giovanna Digiesi; Diana Giannarelli; Isabella Sperduti; Matteo Molica; Massimo Gentile; Fortunato Morabito; Antonino Neri; Manlio Ferrarini
Journal:  Int J Hematol       Date:  2008-09-27       Impact factor: 2.490

9.  Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey.

Authors:  Michael Steurer; Helga Wagner; Günther Gastl
Journal:  Wien Klin Wochenschr       Date:  2004-06-30       Impact factor: 1.704

10.  Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia.

Authors:  S Molica; G Vitelli; D Levato; A Ricciotti; G Digiesi
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.